Non-Hodgkin Lymphoma (NHL)

Latest News

Lori A. Leslie, MD | Image: John A. Theurer Cancer Center

Phase 2 Study Shows Feasibility of Axi-Cel Delivery in Outpatient Setting

By Mary Caffrey

September 13th 2025

Outpatient treatment with axi-cel shows promising response rates for relapsed large B-cell lymphoma, enhancing accessibility in community oncology settings.

Bijal Shah, MD, MS | Image: Moffitt Cancer Center

Indirect Comparison Finds Zanubrutinib Associated With Better PFS, OS Than Acalabrutinib in MCL

By Mary Caffrey

September 12th 2025

Lai Wang, PhD | Image: BeOne Medicines

Positive Topline Results Seen for Sonrotoclax in R/R Mantle Cell Lymphoma

By Mary Caffrey

September 4th 2025

Drug label | Image: Adobe Stock

Many Uncertainties With New Cancer Drugs Don’t Make it to FDA Label, Study Finds

By Mary Caffrey

August 20th 2025

T-cell attacking cancer cell | Image: NCI

How In Vivo CAR T-Cell Therapies Could Rewrite the Cancer Care Playbook

August 20th 2025

Continuing Medical Education

September 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 16th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

September 16th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

September 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

September 16th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Health care costs graphic | Image credit: wladimir1804 – stock.adobe.com

January 19th 2024

Study Highlights Treatment Patterns, Costs for DLBCL Not Treated With Stem Cell Transplant

Hayden E. Klein

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

January 12th 2024

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

January 8th 2024

Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R/R Follicular Lymphoma

Lymphoma cells | Image credit: LASZLO - stock.adobe.com

September 22nd 2023

Salvage RT Shows Local Control in LBCL After CAR T-Cell Therapy Failure

Salvage radiation therapy (RT) showed efficacy in local control of relapsed or refractory large B-cell lymphoma (LBCL) following CD19-targeted chimeric antigen receptor (CAR) T-cell therapy failure.

Diffuse large B-cell lymphoma | Image credit: David A Litman - stock.adobe.com

September 21st 2023

Subcutaneous Epcoritamab Elicits Durable Responses in R/R LBCL

Subcutaneous epcoritamab produced deep and durable complete remissions in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), with complete responders having favorable long-term outcomes, according to updated data from the phase 1/2 EPCORE NHL-1 trial.

CT machine | Image credit: MyPixelArtStudios - stock.adobe.com

September 15th 2023

Novel PET-Based Radiomics Signature Predicts CAR T Efficacy in DLBCL

A PET-based radiomics signature was able to predict the efficacy of chimeric antigen receptor (CAR) T-cell therapy and performed better than conventional PET biomarkers in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Blood cells | Image credit: Катерина Євтехова - stock.adobe.com

September 7th 2023

Review Highlights Knowledge Gaps in Lymphoma Treatment Outcomes in AYAs

The review summarized existing evidence around short- and long-term treatment-related toxicities among adolescents and young adults (AYAs), as well as gaps in care guidelines for AYA survivors of lymphoma.

Blood flowing

August 18th 2023

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL, Follicular Lymphoma

The European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) for odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) following disease progression after at least 2 prior lines of systemic therapy.

CAR T-cell therapy

August 11th 2023

Axi-Cel Extends Survival vs Standard of Care for R/R LBCL

An overall survival (OS analysis of the phase 3 ZUMA-7 trial demonstrated longer OS in patients treated with axicabtagene ciloleucel (axi-cel) vs the standard of care for early relapsed or refractory (R/R) large B-cell lymphoma (LBCL).

Senior sad man leans on a cane while sitting on sofa: © LIGHTFIELD STUDIOS - stock.adobe.com

August 1st 2023

Despite Novelty, Fluid Overload–Associated LBCL Has Distinguishing Features

Jared Kaltwasser

Investigators said the fact that their patient was 82 years old was one reason to suspect fluid overload–associated large B-cell lymphoma (LBCL).

Doctor holding in his hands two silicone implants. Female patient trying to touch them: © Yakobchuk Olena - stock.adobe.com

July 31st 2023

Amid Increasing Breast Implant–Related EBV+ DLBCL Cases, Researchers Share Insights on the Disease

Jaime Rosenberg

Recognition of the association between breast implants and lymphomas has been notable since the 1990s, although the association has been limited to breast implant–associated anaplastic large cell lymphoma and not Epstein-Barr virus (EBV).

Blood vial and hepatitis B | Image Credit: © alexskopje - stock.adobe.com

July 29th 2023

Treated Hepatitis B Infection May Be a Positive Prognostic Factor in Patients With DLBCL

Those with the infection who underwent treatment exhibited improved outcomes compared with patients without the infection.

Endocrinology doctor consulting lymphoma patient with sore neck, aching swollen lymph nodes, throat pain, laryngitis, hodgkin symptoms. Healthcare specialist medical appointment in clinic office: © DC Studio - stock.adobe.com

July 27th 2023

Review Details Current Understanding, Future Directions of DLBCL in Patients With HIV

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin subtype in individuals living with HIV.

Heart and DNA Image

July 22nd 2023

In DLBCL Treatment, Cardiovascular Comorbidities Warrant Careful Consideration

Jared Kaltwasser

The most common treatments come with significant cardiovascular risk, but study investigators suggest newer options might offer a more favorable risk profile.

Symbol of pancreatic cancer. Purple awareness ribbon: © Vitalii Vodolazskyi - stock.adobe.com

July 18th 2023

In Pancreatic DLBCL, Older Age, Distant Stage, Lack of Surgery Lead to Worse Outcomes

Jared Kaltwasser

Surgery can be difficult in such cases of diffuse large B-cell lymphoma (DLBCL), but it leads to significant better outcomes, study authors said.

Colorful cell interaction - tumor cell surrounded with immune cells (Generative AI): © Nevio - stock.adobe.com

July 11th 2023

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

These findings from research into diffuse large B cell lymphoma (DLBCL) are based on analyses of human patients and a murine model.

PET/CT is a nuclear medicine device that uses a combination of PET (Positron Emission Tomography) and Computed Tomography technology to diagnose cancer. Brain and nervous system myocardial ischemia: © workphoto - stock.adobe.com

July 8th 2023

Complicated Case of DLBCL Shows Limits of 18F-FDG PET/CT Imaging

Jared Kaltwasser

Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).

White blood cells in leukemia, AI Generative: © Катерина Євтехова - stock.adobe.com

July 5th 2023

Evolutionary Dynamics Drive Behind Outcomes in Late DLBCL Relapses

Jared Kaltwasser

Serial biopsies help explain why patients with late relapses of diffuse large B-cell lymphoma (DLBCL) fare better than those with early relapses.

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

June 28th 2023

Topline Results Show Epcoritamab Offers 82% Response Rate in R/R Follicular Lymphoma

The bispecific antibody received an accelerated approval in May to treat patients with R/R diffuse large B-cell lymphoma.

Finding solutions to complex cases from several perspectives. High angle shot of a group of medical practitioners having a discussion together in a hospital: © Kirsten D/peopleimages.com - stock.adobe.com

June 27th 2023

Patient Complaining of Abdominal Pain Found to Have Unusual Case of DLBCL

Jared Kaltwasser

The patient was put on chemotherapy, but then underwent surgical resection following an accident at home.

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

June 22nd 2023

New Epcoritamab Data Show Strong Results in B-Cell Lymphomas

Jared Kaltwasser

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

researchers in a lab

June 17th 2023

Epcoritamab Sparks Durable Responses in Phase 1/2 LBCL Trial

Jared Kaltwasser

At a median follow-up of 10.7 months, the overall response rate was 63.1%.

chest pain

June 16th 2023

Investigators Find DLBCL When Probing Apparent Intramural Hematoma

Jared Kaltwasser

The case report highlights the importance of considering diffuse large B-cell lymphoma (DLBCL) when evaluating patients with persistent periaortic fluid collections.

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

June 9th 2023

Epcoritamab Approval Expands Treatment Armamentarium for DLBCL

Mary Caffrey Rose McNulty

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.

depressed older man sitting with his head in his hand

June 8th 2023

Preexisting Mental Health Disorders Worsen DLBCL Prognosis

Laura Joszt, MA

Patients with depression, anxiety, or both at the time of diagnosis of diffuse large B-cell lymphoma (DLBCL) have worse overall survival and lymphoma-specific survival.

science background

June 7th 2023

Review: Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Jared Kaltwasser

New therapies could potentially target immune systems at play in certain types of diffuse large B-cell lymphoma.

FDA approved

May 19th 2023

Epcoritamab Approved by FDA to Treat R/R DLBCL

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

ASH 2022: Bispecific Antibodies

February 4th 2023

ASH 2022: Bispecific Antibodies

Mary Caffrey Hayden E. Klein

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Graphic with the words "Top 5 Clinical Spotlight Interviews of 2022"

December 29th 2022

Top 5 Clinical Spotlight Interviews of 2022

Throughout 2022, expert interviews on clinical topics covered cytogenetics in multiple myeloma, access to better treatments in diffuse large B-cell lymphoma, and challenges with devices in chronic obstructive pulmonary disease.

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions